Sun Pharmaceutical Intrinsic Value
SUNPHARMA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1144.00 | ₹915.20 - ₹1372.80 | -35.8% | EPS: ₹52.00, Sector P/E: 22x |
| Book Value Method | asset | ₹4456.50 | ₹4010.85 - ₹4902.15 | +150.0% | Book Value/Share: ₹3020.25, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹3565.20 | ₹3208.68 - ₹3921.72 | +100.0% | Revenue/Share: ₹2479.17, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹3565.20 | ₹3208.68 - ₹3921.72 | +100.0% | EBITDA: ₹19696.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹4456.50 | ₹3565.20 - ₹5347.80 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹534.78 | ₹481.30 - ₹588.26 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹803.40 | ₹723.06 - ₹883.74 | -54.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹3565.20 | ₹3208.68 - ₹3921.72 | +100.0% | ROE: 17.2%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹1879.81 | ₹1691.83 - ₹2067.79 | +5.5% | EPS: ₹52.00, BVPS: ₹3020.25 |
Want to compare with current market value? Check SUNPHARMA share price latest .
Valuation Comparison Chart
SUNPHARMA Intrinsic Value Analysis
What is the intrinsic value of SUNPHARMA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Sun Pharmaceutical (SUNPHARMA) is ₹3565.20 (median value). With the current market price of ₹1782.60, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹534.78 to ₹4456.50, indicating ₹534.78 - ₹4456.50.
Is SUNPHARMA undervalued or overvalued?
Based on our multi-method analysis, Sun Pharmaceutical (SUNPHARMA) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 37.04 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.27 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 17.2% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 31.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.65x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Sun Pharmaceutical
Additional stock information and data for SUNPHARMA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹14,072 Cr | ₹11,481 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹12,135 Cr | ₹11,754 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹4,959 Cr | ₹1,349 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹8,985 Cr | ₹6,207 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹6,170 Cr | ₹6,170 Cr | Positive Free Cash Flow | 8/10 |